Blood Test Accurately Predicts Five-Year Alzheimer’s Risk

 

Is your doctor competent? enough to have this test ready for you; AND  have EXACT DEMENTIA PREVENTION PROTOCOLS READY,  based on your risk of dementia post stroke?

Your risk of dementia, has your doctor told you of this?  Your doctor is responsible for preventing this! Is s/he willing to prevent this?

1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.

2. Then this study came out and seems to have a range from 17-66%. December 2013.`    

3. A 20% chance in this research.   July 2013.

4. Dementia Risk Doubled in Patients Following Stroke September 2018 

The latest here:

Blood Test Accurately Predicts Five-Year Alzheimer’s Risk

Summary: A new study establishes the long-term prognostic power of the blood-based biomarker p-tau217. The analysis reveals that asymptomatic individuals presenting with very high baseline p-tau217 concentrations face an absolute 38% risk of developing cognitive impairment within 5 years, escalating to 78% within 10 years.

This predictive capability operates entirely independent of amyloid PET plaque profiles and APOE4 genetics, providing a validated screening standard to select high-risk candidates for targeted Alzheimer’s disease prevention trials.

Key Facts

• The 5-Year and 10-Year Risk Trajectories: The study successfully converted raw p-tau217 biomarker levels into individual risk forecasts. Cognitively healthy older adults who registered “very high” baseline p-tau217 levels demonstrated a 38% absolute risk of developing cognitive impairment within 5 years. Over a 10-year horizon, that predictive risk escalated dramatically to 78%.
• Total Independence from Other Risk Factors: Crucially, the p-tau217 biomarker predicted future cognitive decline entirely independent of other established risk profiles. Its mathematical accuracy held firm even when accounting for the physical presence of amyloid-beta plaques on PET scans or high-risk genetic variations like the APOE4 allele.
• Current Asymptomatic Clinical Restraint: Despite the high accuracy of the test, Dr. Reisa Sperling emphasizes that currently available blood tests are not recommended for healthy, asymptomatic individuals in everyday clinical practice. Because there are no approved disease-modifying therapies for asymptomatic pre-clinical stages, a positive test cannot alter standard medical options.
• The Clinical Standard Recommendation: For any individual discovering a high-risk profile today, the foundational medical guidance remains strictly behavioral and preventative: regular cardiovascular exercise, a highly nutritious diet, strict sleep prioritization, and aggressive overall metabolic wellness tracking.(DEMAND your doctor PROVIDE EXACT PREVENTION PROTOCOLS! None of this useless guideline crapola! The need has been known for decades! That's a long time to BE COMPLETELY INCOMPETENT!) 
• The “Cholesterol Test” Target: The ultimate goal of the Mass General Brigham team is to mature p-tau217 testing into the neurological equivalent of a standard cardiovascular cholesterol screening, providing an accessible tool that safely guides proactive monitoring and early clinical interventions years before a devastating event occurs.
• Gateway to Clinical Prevention Trials: The primary immediate application for p-tau217 testing is the rapid, low-cost screening of ideal candidates for ongoing disease-modifying therapy clinical trials. By identifying individuals with high risk before symptoms manifest, researchers can test preventive treatments when the brain is most receptive to preservation.

Source: Mass General

A blood test for the biomarker phosphorylated tau 217 (p-tau217) recently received federal clearance, but questions have emerged around the extent to which such tests can accurately predict whether a cognitively healthy individual will go on to develop cognitive impairment—a key symptom of Alzheimer’s disease.

A new, international study involving researchers across three continents and led by experts from the Mass General Brigham Neuroscience Institute sheds new light on the prognostic value of such tests.

The study found that cognitively unimpaired individuals with very high levels of the biomarker had a 38% absolute risk of developing cognitive impairment over the next five years—and higher risk over the next 10 years.

A high baseline p-tau217 blood draw acts as an independent prognostic clock, predicting a 38% absolute risk of clinical cognitive impairment within 5 years and a 78% risk within 10 years. Credit: Neuroscience News

Results are presented at the Alzheimer’s Association International Conference and simultaneously published in JAMA.

“We do not yet have disease-modifying treatments for people who find out they are at high risk for developing cognitive impairment due to Alzheimer’s disease, which is why we don’t recommend currently available blood tests for asymptomatic individuals.

Today, our medical advice would remain the same regardless of test results: exercise regularly, maintain a healthy diet, and prioritize sleep and overall wellness,” said senior and corresponding author Reisa Sperling, MD, a neurologist with the Mass General Brigham Neuroscience Institute.

“But the preventive care landscape could change rapidly if ongoing trials of disease-modifying therapies prove beneficial. In the future, these tests could help identify those who might benefit most from these treatments. Our long-term goal is to get us to where cholesterol testing is in predicting your risk of a heart attack.”

To conduct their study, investigators pooled data from across six observational and clinical trial studies based in North America, Japan, and Australia. The studies included 2,684 cognitively unimpaired older adults. Blood samples were tested for p-tau217 levels and PET imaging was conducted when participants enrolled in the studies to get a baseline reading. Participants received annual follow-ups to assess cognitive function. The earliest enrollment in one of the studies was in 2004, and the most recent follow-up was in 2025.

The research team charted participants’ cognitive trajectories, quantifying their risk of developing cognitive impairment over time. Approximately 478 participants progressed to cognitive impairment. Higher p-tau217 levels at baseline were significantly associated with cognitive impairment. Individuals with very high p-tau217 levels had a 38% risk of developing cognitive impairment over five years. This risk grew with time, reaching 78% over 10 years. However, data were much sparser for 10-year outcomes and beyond.

“This is a critical step toward better understanding what p-tau217 can tell us about a person’s risk for cognitive impairment,” said lead author Rachel F. Buckley, PhD, a cognitive neuroscientist with the Mass General Brigham Neuroscience Institute. “What really sets this work apart is that it estimates an individual’s level of risk for cognitive impairment. We harmonized data across six cohorts, creating a large and varied data set, and still found consistent results showing how p-tau217 informs risk over time.”

Researchers found that the blood test predicted risk independent of other known risk factors, including amyloid-beta plaques that can appear on PET scans and known genetic risk factors (such as APOE4). While the study’s design has many strengths, it is still limited by selection bias and focuses on relatively short-term risks, rather than over a lifetime. Future work is needed to validate the findings in broader and more representative populations. By following participants over longer periods, researchers will be able to further refine individual risk estimates.